On Thursday (January 4th) local time, Danish pharmaceutical giant Novo Nordisk announced on its official website that it has reached research cooperation agreements with two American biotech companies, Omega Therapeutics, Inc. and Cellarity Inc., respectively. Specifically, Novo Nordisk will utilize Omega's proprietary platform technology to develop "epigenome controller" drugs that can adjust gene expression without altering the natural nucleic acid sequence of the human body. Novo Nordisk hopes to develop drugs that can enhance cellular metabolic activity as a new method for treating obesity.